当前位置:
X-MOL 学术
›
Genet. Test. Mol. Biomark.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Clinical Effect of Driver Mutations of KRAS, CDKN2A/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis
Genetic Testing and Molecular Biomarkers ( IF 1.1 ) Pub Date : 2020-12-16 , DOI: 10.1089/gtmb.2020.0078 Yujun Gu 1 , Yayun Ji 2 , Hui Jiang 3 , Ganbin Qiu 3
Genetic Testing and Molecular Biomarkers ( IF 1.1 ) Pub Date : 2020-12-16 , DOI: 10.1089/gtmb.2020.0078 Yujun Gu 1 , Yayun Ji 2 , Hui Jiang 3 , Ganbin Qiu 3
Affiliation
Objective: To evaluate the prognostic value of driver mutations in the KRAS, CDKN2A/P16, TP53, and SMAD4 genes in pancreatic cancer to aid in the design of therapeutic strategies.
中文翻译:
胰腺癌中KRAS,CDKN2A / P16,TP53和SMAD4驱动突变的临床效果:荟萃分析
目的:评估胰腺癌KRAS,CDKN2A / P16,TP53和SMAD4基因驱动突变的预后价值,以帮助设计治疗策略。
更新日期:2020-12-22
中文翻译:
胰腺癌中KRAS,CDKN2A / P16,TP53和SMAD4驱动突变的临床效果:荟萃分析
目的:评估胰腺癌KRAS,CDKN2A / P16,TP53和SMAD4基因驱动突变的预后价值,以帮助设计治疗策略。